Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

ClinicalTrials.gov ID: NCT00509145

Public ClinicalTrials.gov record NCT00509145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS

Study identification

NCT ID
NCT00509145
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
1,106 participants

Conditions and interventions

Interventions

  • Laquinimod Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 12, 2007
Primary completion
Nov 7, 2010
Completion
Nov 7, 2010
Last update posted
Nov 1, 2021

2007 – 2010

United States locations

U.S. sites
23
U.S. states
19
U.S. cities
23
Facility City State ZIP Site status
Teva Investigational Site 1076 Phoenix Arizona 85004
Teva Investigational Site 1090 Centennial Colorado 80112
Teva Investigational Site 1088 Fort Collins Colorado 80528
Teva Investigational Site 1094 New Haven Connecticut 06520-8018
Teva Investigational Site 1102 Northbrook Illinois 60062
Teva Investigational Site 1081 Fort Wayne Indiana 46805
Teva Investigational Site 1083 Des Moines Iowa 50314
Teva Investigational Site 1086 Kansas City Kansas 66160
Teva Investigational Site 1101 Lexington Kentucky 40513
Teva Investigational Site 1096 Farmington Hills Michigan 48334
Teva Investigational Site 1093 Minneapolis Minnesota 55414
Teva Investigational Site 1098 St Louis Missouri 63104
Teva Investigational Site 1082 New York New York 10003
Teva Investigational Site 1079 Rochester New York 14642
Teva Investigational Site 1073 Winston-Salem North Carolina 27157
Teva Investigational Site 1097 Fargo North Dakota 58103
Teva Investigational Site 1084 Dayton Ohio 45417
Teva Investigational Site 1092 Oklahoma City Oklahoma 73120
Teva Investigational Site 1100 Hershey Pennsylvania 17033-0850
Teva Investigational Site 1087 Philadelphia Pennsylvania 19104
Teva Investigational Site 1075 Lubbock Texas 79410
Teva Investigational Site 1078 San Antonio Texas 78231
Teva Investigational Site 1085 Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 121 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00509145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 1, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00509145 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →